Literature DB >> 14679203

Merlin neutralizes the inhibitory effect of Mdm2 on p53.

Hongtae Kim1, Noh-Jin Kwak, Joo Yong Lee, Byung Hyune Choi, Young Lim, Young Jin Ko, Young-Hoon Kim, Pil-Woo Huh, Kweon-Haeng Lee, Hyoung Kyun Rha, Young-Pil Wang.   

Abstract

The stability of p53 tumor suppressor is regulated by Mdm2 via the ubiquitination and proteasome-mediated proteolysis pathway. The c-Abl and PTEN tumor suppressors are known to stabilize p53 by blocking the Mdm2-mediated p53 degradation. This study investigated the correlation between p53 and merlin, a neurofibromatosis 2 (NF2)-related tumor suppressor, in association with the Mdm2 function. The results showed that merlin increased the p53 stability by inhibiting the Mdm2-mediated degradation of p53, which accompanied the increase in the p53-dependent transcriptional activity. The stabilization of p53 by merlin appeared to be accomplished through Mdm2 degradation, and the N-terminal region of merlin was responsible for this novel activity. This study also showed that overexpression of merlin-induced apoptosis of cells depending preferentially on p53 in response to the serum starvation or a chemotherapeutic agent. These results suggest that merlin could be a positive regulator of p53 in terms of tumor suppressor activity, and provide the promising therapeutic means for treating tumors with non-functional merlin or Mdm2 overexpression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679203     DOI: 10.1074/jbc.M305526200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  The role of NF2 gene mutations and pathogenesis-related proteins in sporadic vestibular schwannomas in young individuals.

Authors:  Hongsai Chen; Xiaoman Zhang; Zhihua Zhang; Tao Yang; Zhaoyan Wang; Hao Wu
Journal:  Mol Cell Biochem       Date:  2014-03-12       Impact factor: 3.396

2.  Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.

Authors:  René G Feichtinger; Serge Weis; Johannes A Mayr; Franz A Zimmermann; Barbara Bogner; Wolfgang Sperl; Barbara Kofler
Journal:  Neuro Oncol       Date:  2015-06-23       Impact factor: 12.300

3.  Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.

Authors:  Hongsai Chen; He Huang; Jingjing Zhao; Zhigang Wang; Mengling Chang; Lu Xue; Weidong Zhu; Yongchuan Chai; Gen Li; Zhaoyan Wang; Hao Wu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

Review 4.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

Review 5.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

6.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

7.  A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Authors:  ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

Review 8.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

Review 9.  Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors:  Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2019-10-06       Impact factor: 12.944

Review 10.  Merlin, the NF2 gene product.

Authors:  Nives Pećina-Šlaus
Journal:  Pathol Oncol Res       Date:  2013-05-12       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.